Kiniksa Pharmaceuticals International, plc
Nasdaq · Healthcare · Pharmaceutical Preparations · London
KNSA chart
What traders are saying about $KNSA
Latest postsKiniksa Pharmaceuticals International, plc news
- Kiniksa Pharmaceuticals International PLC (KNSA) Shares Fall 3.8% -- What GF Score of 46 Tells Investors
GuruFocus ·
- Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Penn Capital Management Company LLC
MarketBeat ·
- 251,578 Kiniksa Pharmaceuticals International, plc $KNSA Shares Bought by Pictet Asset Management Holding SA
MarketBeat ·
- Kiniksa Stock In Focus After Stronger Earnings Per Share
Simply Wall St ·
- Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week High - What's Next?
MarketBeat ·
- Is Kiniksa Pharmaceuticals International (KNSA) Undervalued As Earnings Per Share Keeps Improving?
Simply Wall St ·
- The Bet Behind Kiniksa’s 123% Run
Simply Wall St ·
- Form 4 Kiniksa Pharmaceuticals International: Sanj K. Patel (Director, CHAIRMAN & CEO) For: 4 November
Investing.com Australia ·
- Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells 151,300 Shares of Stock
MarketBeat ·
- At $17.92 a share, Kiniksa (KNSA) CEO exercises options; his trust sells 151,300 shares.
Stock Titan ·
- Kiniksa Pharmaceuticals International Insiders Sold US$16m Of Shares Suggesting Hesitancy
Moomoo ·
- Stock Market: Google, Amazon, Intel, ServiceNow Trigger Tech Wreck, But Other Sectors Solid: Weekly Review
Yahoo Finance ·
Kiniksa Pharmaceuticals International, plc key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $677.6M | $423.2M | $270.3M | $220.2M |
| Net income | $59.0M | -$43.2M | $14.1M | $183.4M |
| Diluted EPS | $0.75 | $-0.60 | $0.20 | $2.60 |
| Total assets (year end) | $763.6M | $580.6M | $526.3M | $459.7M |
| Cash and equivalents (year end) | $165.6M | $183.6M | $108.0M | $122.7M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Kiniksa Pharmaceuticals International, plc
- Ticker
- KNSA (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- London
- Fiscal year end
- December 31
- SEC CIK
- 1730430
- Former names
- Kiniksa Pharmaceuticals, Ltd.
Frequently asked questions
What exchange is Kiniksa Pharmaceuticals International, plc listed on?
Kiniksa Pharmaceuticals International, plc trades on the Nasdaq under the ticker symbol KNSA.
What industry is Kiniksa Pharmaceuticals International, plc in?
Kiniksa Pharmaceuticals International, plc is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Kiniksa Pharmaceuticals International, plc headquartered?
Kiniksa Pharmaceuticals International, plc's business address on file with the SEC is in London.
When does Kiniksa Pharmaceuticals International, plc's fiscal year end?
Kiniksa Pharmaceuticals International, plc's fiscal year ends on December 31.
How much revenue did Kiniksa Pharmaceuticals International, plc report?
Kiniksa Pharmaceuticals International, plc reported $677.6M in revenue for calendar year 2025, according to its SEC filings.